Journal article
Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling
Saber Dini, Sophie Zaloumis, Pengxing Cao, Ric N Price, Freya J Fowkes, E Rob W van der Pluijm, James M McCaw, Julie A Simpson
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | AMER SOC MICROBIOLOGY | Published : 2018
DOI: 10.1128/AAC.01068-18
Abstract
The first line treatment for uncomplicated falciparum malaria is artemisinin-based combination therapy (ACT), which consists of an artemisinin derivative coadministered with a longer-acting partner drug. However, the spread of Plasmodium falciparum resistant to both artemisinin and its partner drugs poses a major global threat to malaria control activities. Novel strategies are needed to retard and reverse the spread of these resistant parasites. One such strategy is triple artemisinin-based combination therapy (TACT). We developed a mechanistic within-host mathematical model to investigate the efficacy of a TACT (dihydroartemisinin-piperaquine-mefloquine [DHA-PPQ-MQ]) for use in South-East ..
View full abstractRelated Projects (5)
Grants
Awarded by NHMRC Centres for Research Excellence in Malaria Elimination
Awarded by Victorian Center for Biostatistics, Infectious Diseases Modeling
Awarded by NHMRC
Awarded by ARC Discovery Project
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
This study was supported by the NHMRC Centres for Research Excellence in Malaria Elimination (1134989), Victorian Center for Biostatistics (1035261), Infectious Diseases Modeling to Inform Public Health Policy (1078068), an NHMRC Project Grant (1100394), and an ARC Discovery Project (DP170103076). F.J.I.F. was supported by Australian Research Council Future Fellowship. R.N.P. is a Wellcome Trust Senior Fellow in Clinical Science (200909), and J.A.S. is a NHMRC Senior Research Fellow (1104975).